Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04880291 · ClinicalTrials.gov registry record · Phase 1
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
A Phase 1 study of Diabetes Mellitus and Kidney Diseases, sponsored by Goldfinch Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT04880291: Completed Phase 1 study of Diabetes Mellitus and Kidney Diseases, sponsored by Goldfinch Bio.
NCT04880291 is a Phase 1 study of Diabetes Mellitus and Kidney Diseases that has completed, run by Goldfinch Bio. The registered enrollment target is 39 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04880291, a Phase 1 study of Diabetes Mellitus and Kidney Diseases, has completed, sponsored by Goldfinch Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
GFB-024 is intended for use in patients with kidney disease such as diabetic nephropathy. This study is the first time GFB-024 has been used in humans. The first part of the study will assess the safety of a single dose of GFB-024 in healthy overweight and obese volunteers and the effect of GFB-024 on the body as compared to an inactive placebo medication. The second part of the study will assess the safety of repeated doses of GFB-024 in participants with Type 2 diabetes and the effect of GFB-024 on the body as compared to an inactive placebo medication.
Primary Outcome
Number of participants with serious and other nonserious adverse events
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GFB-024
Study Locations (1)
Texas
- Worldwide Clinical Trials - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2021-05-05 |
| Est. Completion | 2022-02-08 |
| Phase | Phase 1 |
What the finished NCT04880291 record still lists
NCT04880291 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (98% lower).
The record links to 5 conditions, with Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04880291 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04880291 about?
NCT04880291 is a clinical study titled "First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes". GFB-024 is intended for use in patients with kidney disease such as diabetic nephropathy. This study is the first time GFB-024 has been used in humans. The first part of the study will assess the safety of a single dose of GFB-024 in healthy overweight and obese volunteers and the effect of GFB-024 ...
What is the current status of trial NCT04880291?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2021-05-05. Estimated completion is 2022-02-08.
What conditions does trial NCT04880291 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Kidney Diseases, Diabetic Nephropathies, Endocrine System Diseases, Diabetes Complications.
What interventions are being tested in trial NCT04880291?
The interventions under investigation include: Placebo (DRUG), GFB-024 (DRUG).
Who is sponsoring clinical trial NCT04880291?
This trial is sponsored by Goldfinch Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04880291 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04880291's enrollment target sits among peer trials
39 168th of 208 higher than 41 of 208 other Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
RECRUITING · Phase 1
-
Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)
COMPLETED · Phase 1
-
Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects
COMPLETED · Phase 1
-
A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome
COMPLETED · Phase 1
-
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI